CATX CMO awarded 150,000 stock options

Perspective Therapeutics, Inc. reported that Chief Medical Officer Markus Puhlmann received a grant of stock options covering 150,000 shares on the grant date of March 2, 2026.

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. reported that Chief Medical Officer Markus Puhlmann received a grant of stock options covering 150,000 shares on the grant date of March 2, 2026. The options were approved by the compensation committee as his annual equity award for 2026 and have an exercise price of $0.0000 per share.

The option award vests and becomes exercisable over four years in 48 substantially equal monthly installments, starting one month after the grant date, so long as he continues serving the company on each vesting date. This is a routine equity compensation grant rather than an open‑market share purchase or sale.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider Puhlmann Markus

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	150,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 150,000 contracts (Direct)

Footnotes (2)

1. F1. The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.
2. F2. Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CATX report for Chief Medical Officer Markus Puhlmann?

Perspective Therapeutics reported that Chief Medical Officer Markus Puhlmann received a grant of stock options for 150,000 shares on March 2, 2026. The options were awarded at an exercise price of $0.0000 per share as his annual equity award for 2026, vesting over four years.

How many stock options did the CATX Chief Medical Officer receive in the latest Form 4?

The Chief Medical Officer received stock options covering 150,000 shares according to the Form 4. These options were granted as his 2026 annual equity award and vest in 48 substantially equal monthly installments over four years, beginning one month after the March 2, 2026 grant date.

Is the CATX insider transaction a purchase or a compensation grant?

The CATX insider transaction is a compensation grant, not an open-market purchase. Markus Puhlmann received 150,000 stock options as an annual equity award, approved by the compensation committee, with an exercise price of $0.0000 and time-based vesting over four years of continued service.

What are the vesting terms of the 150,000 CATX stock options granted to the CMO?

The 150,000 stock options vest and become exercisable over four years in 48 substantially equal monthly installments. Vesting begins one month after the March 2, 2026 grant date and is conditioned on Markus Puhlmann’s continued service with the company on each vesting date.

Who approved the 2026 stock option grant reported in CATX’s Form 4?

The option grant was approved by the Compensation Committee of Perspective Therapeutics’ Board of Directors. It was approved on February 4, 2026, with a grant date of March 2, 2026, and represents Chief Medical Officer Markus Puhlmann’s annual equity award for the year 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puhlmann Markus

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.35	03/02/2026(1)		A		150,000		(2)	03/02/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

2. Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

	/s/ Markus Puhlmann by Chris Nenno, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.